What adjunctive treatments can be added to sertraline (Zoloft) for a patient who remains symptomatic despite maximal dosing?

Adjunctive Treatment Options for Sertraline Non-Response

For patients who remain symptomatic despite maximal sertraline dosing, the most evidence-supported adjunctive strategies include adding cognitive behavioral therapy (CBT), augmenting with bupropion, or switching to another SSRI or SNRI rather than augmenting. 1

First-Line Adjunctive Strategies

Cognitive Behavioral Therapy Augmentation

• Adding CBT to ongoing sertraline is equally effective as switching to another medication or augmenting with other pharmacologic agents 1
• The STAR*D trial demonstrated similar efficacy between augmenting citalopram (another SSRI) with CBT versus augmenting with bupropion SR or buspirone 1
• CBT augmentation had numerically lower discontinuation rates due to adverse events (9.2%) compared to medication augmentation (18.8%), though this difference did not reach statistical significance 1

Bupropion Augmentation

• Bupropion combined with sertraline has demonstrated efficacy in treatment-refractory depression through synergistic effects on serotonergic, dopaminergic, and noradrenergic systems 2
• In STAR*D, bupropion SR augmentation showed similar efficacy to buspirone augmentation, but with significantly lower discontinuation rates due to adverse events (12.5% vs 20.6%, p<0.001) 1
• The combination is generally well-tolerated without significant adverse effects in clinical case series 2

Mirtazapine Augmentation

• Adding mirtazapine 30 mg/day to sertraline showed equivalent efficacy to switching from sertraline to mirtazapine alone 1
• In PTSD specifically, sertraline plus mirtazapine demonstrated significantly greater remission rates (p=0.042) and improvement in depressive symptoms (p=0.023) compared to sertraline plus placebo 3
• Both treatments were well-tolerated, with increased appetite but not significant weight gain in the combination group 3

Alternative Augmentation Strategies

Aripiprazole Augmentation

• Low-dose aripiprazole (2.5 mg/day) combined with sertraline 50 mg/day showed significantly better efficacy than sertraline alone in HAM-D17 scores at weeks 1,2, and 4 4
• Particular improvement was noted in "work and social activities" at week 2 and "somatic symptoms (GI)" at week 1 4
• No akathisia was reported during the trial period with this low-dose regimen 4
• One small trial showed aripiprazole augmentation superior to bupropion augmentation (55.4% vs 34.0% remission, p=0.031) 1

Mianserin Augmentation

• Adding mianserin 30 mg/day to sertraline 100 mg/day resulted in 67% response rate in sertraline non-responders, similar to continuing sertraline alone (70%) 5
• This strategy may be considered when other augmentation options are unavailable 5

Strategies That Lack Strong Evidence

Dose Escalation

• Increasing sertraline from 100 mg/day to 200 mg/day resulted in a lower response rate (56%) compared to continuing 100 mg/day (70%, p<0.05) 5
• Higher sertraline doses may increase adverse effects without proportional efficacy gains 6
• The dose-response relationship shows therapeutic response increases with dosage, but adverse reactions increase above 150 mg 7

Atomoxetine Augmentation

• Adding atomoxetine 40-120 mg/day to sertraline showed no difference in symptom improvement or remission rates compared to placebo (40.3% vs 37.8%, p=0.865) 8
• This strategy is not recommended based on current evidence 8

Important Safety Considerations

Serotonin Syndrome Risk

• When combining sertraline with other serotonergic agents, monitor closely for serotonin syndrome, especially in the first 24-48 hours after dosage changes 6, 9
• Symptoms include mental status changes, autonomic instability, neuromuscular symptoms, and gastrointestinal disturbances 9
• Avoid combining with MAOIs, and use caution with tramadol, triptans, other antidepressants, and St. John's Wort 6, 9

Discontinuation Syndrome

• Sertraline is associated with discontinuation syndrome characterized by dizziness, nausea, sensory disturbances, and anxiety 6
• When switching strategies, taper sertraline gradually rather than abruptly discontinuing 9

Bleeding Risk

• Sertraline increases bleeding risk, particularly when combined with NSAIDs, aspirin, or anticoagulants 9
• Monitor INR carefully in patients taking warfarin 9

Clinical Algorithm

Step 1: Confirm adequate sertraline trial (at least 8 weeks at maximum tolerated dose, typically 150-200 mg/day) with verified adherence 6

Step 2: Reassess diagnosis and address contributing factors (substance use, medical comorbidities, medication adherence) 1

Step 3: Choose augmentation strategy based on:

• If CBT available and patient motivated: Add CBT to ongoing sertraline 1
• If medication augmentation preferred: Add bupropion SR (starting 37.5 mg, titrate to 150 mg twice daily) 1
• If prominent anxiety/insomnia: Consider mirtazapine 7.5-30 mg at bedtime 3
• If rapid improvement needed: Consider low-dose aripiprazole 2.5 mg/day 4

Step 4: If no response after 4-6 weeks of adequate augmentation trial, consider switching to a different SSRI, SNRI, or clozapine for treatment-resistant cases 1

Common Pitfall: Increasing sertraline dose above 150 mg without first attempting augmentation or switching strategies, as higher doses may reduce efficacy while increasing adverse effects 5, 7